1. Updates in Best Practices in Non-Small Cell Lung Cancer

3. Program Overview

4. Treatment Schema for Patients with NSCLC

5. Molecular Testing Is Key

6. EGFR-Targeted Agents With Features of the TKIs

7. How to Select Between EGFR TKIs

8. ARCHER 1050 Study: Dacomitinib vs Gefitinib in EGFR Mutation-Positive Lung Cancer

9. Dacomitinib Dose Adjustment Does Not Affect PFS

10. Sequencing Therapy

11. NSCLC Evolves Over Time

12. AURA 3 Trial: Assessing Acquired Resistance Mutations

13. Osimertinib is Active in Patients With Brain Metastases

14. Multidisciplinary Management Important for Treatment of NSCLC With Brain Metastases

15. Is Cure Possible?

16. Resistance in EGFR-Positive NSCLC

17. How to Deal With Resistance

18. ASPIRATION study

19. EGFR TKI in Combination with Anti-Angiogenic Agents

20. Gefitinib + Chemotherapy Shows a Survival Benefit

21. ALK Inhibitors Summary

22. Front-Line Selection of ALK TKI

23. Resistance to ALK TKI

24. The Future for EGFR and ALK TKI

25. Immunotherapy an Option After Progression?

26. Concluding Remarks

27. Abbreviations